TAS-301 (CAS 193620-69-8)
QUICK LINKS
TAS-301 is a compound explored extensively in the domain of vascular biology and pathology research due to its impact on smooth muscle cell migration. This small molecule is particularly significant in investigations concerning the process of intimal hyperplasia. By inhibiting the migration of smooth muscle cells, TAS-301 has become a useful tool in studying the cellular mechanisms that contribute to the narrowing of blood vessels and the subsequent effects on blood flow. Additionally, it is involved in research aimed at understanding the underlying causes of atherosclerosis and restenosis, providing insights into the molecular pathways that are related to these conditions. The action of TAS-301 in modulating cellular processes also extends to research regarding the formation of stable and functional tissue constructs.
TAS-301 (CAS 193620-69-8) References
- Inhibitory effect of TAS-301, a new synthesized constrictive remodeling regulator, on renarrowing after balloon overstretch injury of porcine coronary artery. | Sasaki, E., et al. 2000. J Pharmacol Exp Ther. 295: 1043-50. PMID: 11082439
- TAS-301 blocks receptor-operated calcium influx and inhibits rat vascular smooth muscle cell proliferation induced by basic fibroblast growth factor and platelet-derived growth factor. | Sasaki, E., et al. 2000. Jpn J Pharmacol. 84: 252-8. PMID: 11138725
- Tas-301, a new synthetic inhibitor of neointimal thickening after balloon injury, inhibits calcium-dependent signal transduction and cytoskeletal reorganization. | Sasaki, E., et al. 2001. Pharmacology. 63: 17-27. PMID: 11408828
- Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. | Kinoshita, M., et al. 2002. J Pharm Sci. 91: 362-70. PMID: 11835196
- Formation of physically stable amorphous drugs by milling with Neusilin. | Gupta, MK., et al. 2003. J Pharm Sci. 92: 536-51. PMID: 12587115
- Effect of adsorbents on the absorption of lansoprazole with surfactant. | Ito, Y., et al. 2005. Int J Pharm. 289: 69-77. PMID: 15652200
- Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. | Mallick, S., et al. 2008. Eur J Pharm Biopharm. 68: 346-51. PMID: 17669640
- Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. | Bahl, D., et al. 2008. Pharm Dev Technol. 13: 255-69. PMID: 18484494
- Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. | Vadher, AH., et al. 2009. AAPS PharmSciTech. 10: 606-14. PMID: 19444620
- Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. | Gryczke, A., et al. 2011. Colloids Surf B Biointerfaces. 86: 275-84. PMID: 21592751
- Palladium-Catalyzed One-Pot Approach to 3-(Diarylmethylene)oxindoles from Propiolamidoaryl Triflate. | Lee, D., et al. 2015. Molecules. 20: 14022-32. PMID: 26247925
- Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. | Bhalani, DV., et al. 2022. Biomedicines. 10: PMID: 36140156
- TAS-301, an inhibitor of smooth muscle cell migration and proliferation, inhibits intimal thickening after balloon injury to rat carotid arteries. | Muranaka, Y., et al. 1998. J Pharmacol Exp Ther. 285: 1280-6. PMID: 9618434
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAS-301, 10 mg | sc-215942 | 10 mg | $140.00 |